NEW YORK (GenomeWeb News) – Ipsen and BioMérieux today announced a collaboration using a theranostics approach to focus on hormone-dependent cancers.
The two French firms will combine their expertise and resources to co-develop therapeutics and companion diagnostic tests. The collaboration will leverage Ipsen's broad portfolio of compounds and BioMérieux's diagnostic tests and focus on prostate and breast cancers, neuroendocrine tumors, and pituitary tomors.
Financial and other terms of the deal were not disclosed.
"Our goal is to reinforce personalized medicine and contribute through this partnership to the novel paradigm in medicine, which is increasingly 'patient driven' rather than 'disease driven,'" Christian Bréchot, vice president of Institut Mérieux, in charge of medical and scientific affairs, and a member of BioMérieux's board, said in a statement.
Ipsen and BioMérieux have a relationship dating back to September 2007, when they announced a deal under which BioMérieux would develop a companion assay to determine which patients were the best candidates for Ipsen's steroid sulfatase enzyme inhibitor BN83495 (Irosustat). The compound is currently in phase I clinical development for the treatment of breast and prostate cancers and in phase II development for the treatment of advanced endometrial cancer.